The current study adds a multimodal perspective by showing that atrophy-based typicality and severity are differentially associated with in vivo Aβ, tau, and cerebrovascular burden and differentially explain cognitive performance in the AD continuum. The gene discussed is MAPT; the disease is Atrophy.